Latest updates

ICGEB mission to Turkey

The Director-General, Dr. Lawrence Banks and a delegation from the ICGEB Headquarters in Trieste, Italy visited Turkey in March 2022 to set the ground for an ICGEB RRC in Turkey.

Read more

Awards for Outstanding CRP Grants 2021

Over the more than 30 years that ICGEB has been providing Funding opportunities through its CRP (Collaborative Research Programme) Grants, reviewers have singled out 1-2 outstanding proposals each year which are particularly worthy of recognition.

Read more

Regenerating a damaged heart- becoming a reality

April 25, 2022 – Forcefield Therapeutics, a new biotechnology company, launched today following £5.5 commitment from Syncona, to develop pioneering, best-in-class therapeutics to protect heart function following acute myocardial infarction (AMI).

Read more

ICGEB mission to Argentina and Peru

The Director-General, Lawrence Banks and a delegation from ICGEB Headquarters in Trieste, Italy visited partner institutes in Member States Argentina and Peru in March, 2022.

Read more
Mauro Giacca

Regenerating a damaged heart can become a reality

March 18, 2022 – Heqet Therapeutics, a King’s College London biotech spin-out active in the field of regenerative medicine, announces the closing of a €8m Series A financing round, to advance its RNA-based therapeutic program for cardiac regeneration.

Read more